Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial.

@article{Arai2008InfusionOT,
  title={Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial.},
  author={Sally Arai and Richard C Meagher and Mike Swearingen and Han Myint and Elizabeth S. Rich and Ja Martinson and H. -G. Klingemann},
  journal={Cytotherapy},
  year={2008},
  volume={10 6},
  pages={625-32}
}
BACKGROUND Renal cell cancer and malignant melanoma are two types of cancer that are responsive to immunotherapy. In this phase I dose-escalation study, the feasibility of large-scale expansion and safety of administering ex vivo-expanded NK-92 cells as allogeneic cellular immunotherapy in patients with refractory renal cell cancer and melanoma were determined. METHODS Twelve patients (aged 31-74 years) were enrolled, three per cohort at cell dose levels of 1x10(8)/m(2), 3x10(8)/m(2), 1x10(9… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 86 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Effectiveness of donor

  • L Ruggeri, M Capanni, E Urbani
  • cell lysis. Immunol Lett 2005;100:7
  • 2005

Cancer: Principles & Practice of Oncology, 7th edition

  • VT DeVita, S Hellman, SA. Rosenberg
  • 2004

Similar Papers

Loading similar papers…